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Summary
Dopamine plays an important role in the etiology
of schizophrenia, and D2 class dopamine receptors
are the best-established target of antipsychotic
drugs. Here we show that D2 class-receptor-mediated
Akt regulation involves the formation of signaling
complexes containing -arrestin 2, PP2A, and Akt.
-arrestin 2 deficiency in mice results in reduction of
dopamine-dependent behaviors, loss of Akt regula-
tion by dopamine in the striatum, and disruption of
the dopamine-dependent interaction of Akt with its
negative regulator, protein phosphatase 2A. Impor-
tantly, canonical cAMP-mediated dopamine-receptor
signaling is not inhibited in the absence of -arrestin
2. These results demonstrate that, apart from its clas-
sical function in receptor desensitization, -arrestin 2
also acts as a signaling intermediate through a ki-
nase/phosphatase scaffold. Furthermore, this func-
tion of -arrestin 2 is important for the expression
of dopamine-associated behaviors, thus implicating
-arrestin 2 as a positive mediator of dopaminergic
synaptic transmission and a potential pharmacologi-
cal target for dopamine-related psychiatric disorders.
Introduction
Neurotransmitters exert their functions by binding to
two broad classes of receptors that are associated with
different dynamic modalities of synaptic transmission.
Ionotropic receptors consist of ligand-gated ion chan-
nels that mediate fast synaptic transmission (Unwin,
1993). In contrast, metabotropic receptors respond to
neurotransmitters by acting through signaling path-
ways and are associated with slow synaptic transmis-
sion (Greengard, 2001; Jessell and Kandel, 1993). A ma-
jor group of metabotropic receptors consists of seven
transmembrane domain proteins (GPCR) that activate
different types of heterotrimeric G proteins (Gainetdi-
nov et al., 2004; Vassilatis et al., 2003).
Dopamine (DA) receptors represent prototypic exam-*Correspondence: caron002@mc.duke.eduples of GPCR mediating neurotransmission (Missale et
al., 1998). DA is a monoamine neurotransmitter involved
in the regulation of locomotion, reward, and affect
(Carlsson, 2001; Gainetdinov and Caron, 2003; Zhou
and Palmiter, 1995). Dysregulation of dopaminergic
neurotransmission is associated with multiple neuro-
logical and psychiatric conditions such as Parkinson’s
disease, Huntington’s disease, attention deficit hyper-
activity disorder (ADHD), mood disorders, and schizo-
phrenia (Carlsson, 2001; Gainetdinov and Caron, 2003).
In the mammalian brain, most dopaminergic neurons
project from the substantia nigra to the striatum, a ma-
jor area of basal ganglia mostly populated by medium
spiny neurons that are responsive to DA (Greengard,
2001). Two classes of GPCR have been shown to medi-
ate all DA functions. D1 class receptors (D1R and D5R)
are mostly coupled to Gαs and positively regulate the
production of the second messenger cAMP and the ac-
tivity of its main neuronal target, protein kinase A (PKA)
(Missale et al., 1998). D2 class receptors (D2R, D3R,
and D4R) couple to Gαi/o, thus downregulating cAMP
production and PKA activity (Missale et al., 1998).
Moreover, this class of DA receptors can also modulate
intracellular Ca2+ levels (Missale et al., 1998; Nishi et
al., 1997), leading to changes in the activity of Ca2+-
regulated signaling proteins such as the protein phos-
phatase calcineurin (PP2B) (Nishi et al., 1997).
We recently demonstrated that prolonged stimulation
of D2 class receptors leads to specific dephosphoryla-
tion/inactivation of the serine/threonine kinase Akt on
its regulatory Thr308 residue (Beaulieu et al., 2004). In-
terestingly, phosphorylation of Akt on its second regu-
latory residue (Ser473) was not affected by DA (Beau-
lieu et al., 2004). Regulation of Akt by DA was observed
in the striatum of mice that display persistently ele-
vated levels of extracellular DA due to a lack of the
DA transporter (DAT-KO mice). Similar changes in Akt
phosphorylation also occurred in normal mice (wt)
treated with direct or indirect DA agonists such as apo-
morphine or amphetamine (Beaulieu et al., 2004). More-
over, depletion of striatal DA in DAT-KO mice or D2
class-receptor blockade resulted in enhanced phos-
phorylation/activation of Akt, thus indicating that D2
class receptors are responsible for the regulation of Akt
by DA (Beaulieu et al., 2004; Emamian et al., 2004).
Dephosphorylation of Akt in response to DA leads to
a reduction of kinase activity and a concomitant activa-
tion of its substrates glycogen synthase kinase 3 α and
β (GSK3α and GSK3β) since both are negatively regu-
lated by Akt (Beaulieu et al., 2004; Cross et al., 1995).
Consequently, pharmacological activation of Akt or in-
hibition of GSK3α/β results in reduction of DA-associ-
ated locomotor activity in both DAT-KO mice and wt
mice treated with amphetamine (Beaulieu et al., 2004;
Gould et al., 2004). Moreover, mice lacking one allele
of the GSK3β gene show markedly reduced locomotor
responses to amphetamine (Beaulieu et al., 2004), while
mice lacking the Akt isoform Akt1 display behavioral
manifestations generally associated with enhanced do-
paminergic responses (Emamian et al., 2004), thus sup-
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262porting a role for the Akt/GSK3 signaling pathway in the R
expression of DA-associated behaviors.
BThe mechanism by which D2 class-receptor activa-
Ation results in a reduction of Akt activity remains to be
Wclarified. Previous investigations have shown that the
stime course of inactivation of Akt following administra-
ttion of DA agonists to wt mice is more sustained and
iless rapid than responses generally observed for bio-
achemical events regulated through canonical G protein/
tcAMP/PKA pathways (Beaulieu et al., 2004). Moreover,
dincrease in striatal cAMP levels or inhibition of PP2B
adid not affect the activity of the Akt/GSK3 signaling
cpathway in the striatum under conditions of enhanced
nDA receptor stimulation (Beaulieu et al., 2004). Taken
dtogether, these observations suggest that a novel
aGPCR signaling mechanism may be involved in the reg-
culation of Akt by DA.
2The scaffolding proteins β-arrestin 1 and β-arrestin 2
i
have been traditionally associated with the termination
o
of GPCR signaling and with receptor internalization
z
(Attramadal et al., 1992; Ferguson et al., 1996). Follow- t
ing GPCR activation and their phosphorylation by h
GPCR kinases (GRKs), β-arrestins bind to the receptors n
to uncouple them from G proteins and participate in t
the recruitment of the endocytic protein complex, thus a
leading to an attenuation of GPCR signaling (Gainetdi- I
nov et al., 2004). However, evidence obtained from het- s
erologous cellular systems suggested that β-arrestins i
can also act as G protein-independent positive media- h
tors of GPCR signaling through scaffolding of signaling A
molecules such as protein kinases (Lefkowitz and d
Shenoy, 2005; Luttrell et al., 1999, 2001). For example, i
stimulation of angiotensin receptors transfected in fi- s
broblasts has been shown to result in the activation of o
extracellular-signal-regulated kinases (ERK1/2) follow- m
ing the formation of protein complexes including (
tβ-arrestin 2, ERK1/2, and ERK regulatory kinases (Luttrell
et al., 2001). Moreover, β-arrestin-mediated GPCR sig-
wnaling displays slower and more sustained kinetics
mthan G protein-mediated signaling in transfected fibro-
Dblasts (Ahn et al., 2004). Nevertheless, the involvement
aof β-arrestin-mediated GPCR signaling in physiological
dparadigms associated with slow synaptic transmission
Dhas remained unexplored. Interestingly, our preliminary
wobservation in mice lacking β-arrestin 2 (βArr2-KO βmice) suggested that lack of β-arrestin 2 may reduce
dthe expression of some DA-dependent behaviors
s(Gainetdinov et al., 2004). Here we used a functional in
a
vivo approach in intact mice to examine the contribu-
t
tion of β-arrestin 2-mediated signaling to the regulation v
of Akt by DA. Our results show that β-arrestin 2 is l
essential for the inactivation of Akt by DA and the full D
expression of behavioral responses to the dopaminergic D
drugs apomorphine and amphetamine. Moreover, the o
function of β-arrestin 2 in this system is mediated through
the formation of a new type of signaling complex in- s
volving β-arrestin 2, Akt, and protein phosphatase 2A b
(PP2A) in response to DA receptor activation. These re- h
sults provide in vivo evidence for a function of β-arres- a
tin 2 as a kinase/phosphatase scaffold involved in DA d
receptor signaling and the biology of slow synaptic m
ttransmission.esults
ehavioral Responses to Dopaminergic Drugs Are
ttenuated in the Absence of -Arrestin 2
e first examined the role of β-arrestin 2 in the expres-
ion of DA-dependent behaviors. Mice lacking β-arres-
in 2 (Bohn et al., 1999) and wt littermates were placed
n locomotor-activity monitors and left to habituate for
period of 1 hr prior to drug injection and then moni-
ored for changes in locomotor activity (Figure 1A). Two
ifferent dopaminergic drugs, the indirect DA agonist
mphetamine, which exerts its action by raising extra-
ellular DA levels, and the direct D1/D2 receptor ago-
ist apomorphine, were used for these tests. These two
rugs were chosen on the basis of their demonstrated
bility to reliably inactivate Akt in the striatum at doses
ompatible with behavioral analysis (Beaulieu et al.,
004). While a lower locomotor activity was observed
n βArr2-KO versus wt in the initial (first 15 min) phase
f habituation (Figure 1A), no difference in either hori-
ontal or vertical activity was observed in vehicle-
reated habituated mice (Figures 1B and 1C). However,
abituated βArr2-KO mice exhibited markedly less pro-
ounced (w75% less) locomotor activation than wt lit-
ermates following administration of two doses of
mphetamine (2 or 3 mg/kg, i.p.) (Figures 1A and 1B).
mportantly, amphetamine-induced stereotypy was
imilar in both genotypes, suggesting that differences
n locomotor activity were not due to a competing en-
ancement of stereotypy in βArr2-KO mice (Figure 1C).
ssessment of climbing responses in rodents to high
oses of the D1/D2 DA receptor agonist apomorphine
s classically used to evaluate responsiveness of post-
ynaptic DA receptors (Wilcox et al., 1980). Injection
f apomorphine (3 mg/kg, s.c.) to habituated βArr2-KO
ice led to only a marginal increase in vertical activity
climbing), while wt were strongly responsive to this
reatment (Figure 1D).
The role of β-arrestin 2 in DA-dependent behaviors
as further examined using DAT-KO mice, a genetic
odel of enhanced dopaminergic neurotransmission.
AT-KO mice develop DA-dependent locomotor hyper-
ctivity when exposed to a novel environment (Gainet-
inov et al., 1999; Giros et al., 1996). Mice lacking both
AT and β-arrestin 2 expression (βArr2-KO/DAT-KO)
ere generated through crossbreeding of DAT-KO and
Arr2-KO mice. βArr2-KO/DAT-KO mice are viable and
o not present obvious abnormalities beyond those de-
cribed in parental strains (Bohn et al., 1999; Giros et
l., 1996). Like mice lacking the DAT, these double mu-
ants display spontaneous hyperactivity in a novel en-
ironment in comparison to both wt and βArr2-KO
ittermates. However, locomotor activity of βArr2-KO/
AT-KO mice was significantly lower in comparison to
AT-KO littermates (Figures 1E and 1F), while the level
f stereotypy was similar (data not shown).
Altogether, these behavioral observations indicate
ignificant disruption in expression of DA-associated
ehaviors in the absence of β-arrestin 2. This can
ardly be explained by the classical role of β-arrestins
s mediators of GPCR desensitization. Under this para-
igm, a lack of β-arrestin 2 should result in enhance-
ent of DA receptor signaling and behavioral response
o DA (Gainetdinov et al., 2003). Rather, these findings
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minergic Stimulation in β-Arrestin 2 Knock-
out Mice
(A) βArr2-KO mice (n = 16) or wt (n = 20) lit-
termates were placed in a locomotor-activity
monitor for an initial period of 60 min and
were then injected (arrow) with amphetamine
(3 mg/kg of body weight, i.p.). Horizontal ac-
tivity was continuously recorded in blocks of
5 min. Significant differences in horizontal
activity were detected over the first 15 min
of recording (p % 0.005). Activity levels of
habituated mice were comparable.
(B and C) Horizontal activity (B) and stereo-
typy time (C) were quantified in habituated
βArr2-KO mice or wt littermates for a period
of 90 min after injection (i.p.) of amphet-
amine (vehicle wt, n = 12, βArr2-KO, n = 12;
2 mg/kg wt, n = 12, βArr2-KO, n = 11; 3 mg/
kg wt, n = 20, βArr2-KO, n = 16).
(D) Vertical-activity time was measured in ha-
bituated βArr2-KO mice or wt littermates for a
period of 60 min after injection (s.c.) of apo-
morphine (vehicle, n = 13; 3 mg/kg, n = 15).
(E) βArr2-KO/DAT-KO mice (n = 14) or DAT-
KO (n = 15) littermates were placed in a loco-
motor-activity monitor for 120 min. Locomo-
tor activity was continuously recorded as to-
tal distance traveled in blocks of 5 min.
(F) Total distance travelled in wt (n = 20),
βArr2-KO (n = 16), DAT-KO (n = 15), and
βArr2-KO/DAT-KO (n = 14) mice for a period
of 60 min in the open field revealed signifi-
cant reduction of hyperactivity in DAT-KO
mice lacking β-arrestin 2. Both βArr2-KO/
DAT-KO and DAT-KO mice were significantly
different from wt and βArr2-KO littermates
(p % 0.05), while no differences were found
between wt and βArr2-KO mice. (For all re-
sults, data are means ± SEM. *, p %0.05.)suggest that β-arrestin 2 promotes some positive mo-
dalities of DA receptor signaling.
-Arrestin 2 Is Essential for the Regulation
of Akt by Dopamine
Since the lack of β-arrestin 2 does not affect striatal DA
release (Bohn et al., 2003), we proceeded to evaluate
whether β-arrestin 2 could be involved in signaling
mechanisms (Figure 2A) known to participate in dopa-
mine action (Beaulieu et al., 2004; Emamian et al., 2004;
Greengard, 2001). Apart from the recently described
action upon the Akt/GSK3 signaling pathway (Beaulieu
et al., 2004), DA has mostly been considered to exert
its behavioral actions by regulating the activity of
cAMP/PKA signaling pathways (Greengard, 2001; Mis-
sale et al., 1998). The protein phosphatase-1 inhibitor
dopamine and cAMP-regulated phosphoprotein, 32
kDa (DARPP-32), is a substrate of PKA whose phos-
phorylation on Thr34 in response to cAMP is regulated
by DA receptors (Greengard, 2001; Nishi et al., 1997).
Moreover, increased phosphorylation of Thr34-DARPP-
32 has been positively associated with the expression
of locomotor responses to DA drugs (Fienberg et al.,
1998; Nally et al., 2003).We thus evaluated whether a β-arrestin 2 deficiency
could lead to reduced responsiveness/phosphorylation
of DARPP-32 as a result of a disruption of PKA-medi-
ated DA receptor signaling. As might be expected,
injection of amphetamine (3 mg/kg, i.p.) to wt mice re-
sulted in a robust elevation of phospho-Thr34-DARPP-
32 levels in the striatum (Figure 2B). However, a marked
increase in striatal DARPP-32 phosphorylation also oc-
curred following administration of amphetamine to βArr2-
KO mice (Figure 2B). In fact, the response of DARPP-
32 to amphetamine was slightly greater in βArr2-KO as
compared to wt mice, possibly as a result of reduced
D1 receptor desensitization, a phenomenon that should
be associated with enhanced locomotor response to
DA drugs. However, despite this slight enhancement in
cAMP/PKA/DARPP-32 signaling, βArr2-KO mice dis-
played profound impairment in DA-associated beha-
viors (Figure 1), thus suggesting the involvement of
other signaling mechanisms.
Regulation of Akt in response to dopaminergic drugs
was then investigated in wt and βArr2-KO mice. As
shown previously (Beaulieu et al., 2004), significant re-
duction of phospho-Thr308-Akt occurred in the stria-
tum of wt mice following injection of amphetamine (3
Cell
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hibition of Akt but Not Activation of DARPP-
32 by Dopamine
(A) Schematic representation of signaling
pathways associated with DA receptor acti-
vation in the striatum. D1R: D1 class DA re-
ceptor; D2R: D2 class DA receptor.
(B) Western blots and densitometric analysis
of phospho-Thr34 DARPP-32 relative levels
in extract prepared from the striatum of wt
or βArr2-KO mice 15 min after injection of 3
mg/kg amphetamine. (n = 5 mice.)
(C–F) Western blots (C and E) and densito-
metric analysis (D and F) of phospho-Thr308
Akt relative levels in extract prepared from
the striatum of wt or βArr2-KO mice at 60
min postinjection of 3 mg/kg amphetamine
(C and D) or 3 mg/kg apomorphine (E and F).
Representative Western blots show results
obtained from two separate striatal extracts
prepared from different mice. Densitometric
analysis was carried out on five mice per
group for amphetamine and ten mice per
group for apomorphine.
(G and H) Western blots (G) and densitomet-
ric analysis (H) of phospho-Thr308 Akt rela-
tive levels in extract prepared from the stria-
tum of wt, DAT-KO, βArr2-KO, and βArr2-KO/
DAT-KO mice under basal conditions (n =
10 mice).
(I and J) Temporal dynamic of Akt (Thr308
and Ser473) phosphorylation as measured
by Western blot analysis at 0, 30, 60, 90, and
120 min after amphetamine injection (2 mg/
kg, i.p.) in wt (I) and βArr2-KO (J) mice (n =
5–10 mice).
For all densitometric analyses, results are
presented in arbitrary units normalized to
phosphoprotein levels observed in vehicle-
treated mice. Phosphoindependent antibod-
ies directed against the different proteins
were used as loading controls. Data are
means ± SEM. *, p% 0.05; **, p% 0.005; ***,
p % 0.001.mg/kg, i.p.) (Figures 2C and 2D) or apomorphine (3 mg/ s
(kg, s.c.) (Figures 2E and 2F). In contrast, administration
of these two drugs had no effect on striatal phospho- t
wThr308-Akt in βArr2-KO mice.
To substantiate these pharmacological observations, e
βwe compared phospho-Thr308-Akt levels in DAT-KO
and βArr2-KO/DAT-KO mice. Our previous observations (
revealed an inhibition of Akt signaling in response toustained DA receptor stimulation in DAT-KO mice
Beaulieu et al., 2004). In line with this, Akt phosphoryla-
ion was reduced in DAT-KO mice as compared to their
t littermates (Figures 2G and 2H). However, no differ-
nces in Akt phosphorylation were found between
Arr2-KO/DAT-KO mice and their βArr2-KO littermates
Figure 2G and 2H).To examine whether the dynamic of Akt regulation by
β-Arrestin 2-Mediated Slow Synaptic Transmission
265DA may be changed in absence of β-arrestin 2, levels
of phospho-Thr308 and phospho-Ser473 Akt were
measured over time following administration of am-
phetamine (2 mg/kg) to wt and βArr2-KO mice. In wt
mice, amphetamine caused a progressive and sus-
tained dephosphorylation of Akt on Thr308 over a
period of 90 min postinjection, while phosphorylation
of Akt on Ser473 was not significantly affected (Figure
2I). In contrast, no such dephosphorylation of Akt was
observed at any time points in βArr2-KO mice (Figure
2J), thus directly demonstrating that β-arrestin 2 is
essential for the regulation of Akt by DA.
Lack of Regulation of Akt by ERK
in the Mouse Striatum
Activation of protein kinases ERK1 and ERK2 is a
known outcome of β-arrestin 2-mediated signaling fol-
lowing stimulation of angiotensin receptors transfected
in fibroblasts (Luttrell et al., 2001). ERK signaling has
also been suggested to enhance Akt phosphorylation
in embryonic cultured striatal neurons exposed to DA
(Brami-Cherrier et al., 2002). To test whether ERK sig-
naling might be involved in the regulation of Akt by DA,
Western blot analyses were carried out to assess
ERK1/2 phosphorylation in wt and βArr2-KO mice un-
der conditions leading to Akt inactivation. As shown in
Figures 3A–3C, similar changes in levels of phospho-
ERK were observed in wt (Figures 3A and 3C) and
βArr2-KO mice (Figures 3B and 3C) at different time
points following administration of a dose of apomor-
phine (3 mg/kg, s.c.) that produced robust dephosphor-
ylation/inhibition of Akt in wt animals (Figure 2). Thus,
DA-dependent ERK signaling does not seem to be af-
fected by a β-arrestin 2 deficiency.Figure 3. Lack of Regulation of Akt by ERK
in Response to Dopamine
(A and B) Western blots of phospho-ERK1/2
(Thr202/Tyr204) in extracts prepared from
the striatum of wt (A) or βArr2-KO (B) mice at
60 min postinjection of apomorphine (3 mg/
kg). Representative Western blots show re-
sults obtained from two separate striatal ex-
tracts prepared from different mice.
(C) Densitometric analysis of striatal phos-
pho-ERK2 levels as measured by Western
blot analysis at 0, 15, and 60 min following
apomorphine injection (3 mg/kg) in wt and
βArr2-KO mice. (n = 5 mice).
(D and E) Western blots (D) and densitomet-
ric analysis (E) of phospho-Thr308 Akt and
phospho-ERK1/2 (Thr202/Tyr204) relative
levels in extracts prepared from the striatum
of DAT-KO mice 60 min after injection of 100
mg/kg of the MEK inhibitor SL327. (n = 5
mice.)
For all densitometric analyses, results are
presented in arbitrary units normalized to
phosphoprotein levels observed in vehicle-
treated mice. Phosphoindependent antibod-
ies directed against the different proteins
were used as loading controls. Data are
means ± SEM. ***, p % 0.001.To further substantiate these observations, SL327, ablood-brain-barrier-permeable selective inhibitor of the
ERK kinase MEK (Valjent et al., 2000), was used. Under
basal conditions, DAT-KO mice exhibit persistently ele-
vated DA tone (Gainetdinov et al., 1999; Jones et al.,
1998), leading to sustained DA-mediated inactivation of
Akt as compared to normal mice (Beaulieu et al., 2004).
Administration of SL327 (100 mg/kg, i.p.) to DAT-KO
mice resulted in a marked reduction of striatal phos-
pho-ERK1/2 levels (Figures 3D and 3E). Nevertheless,
inhibition of ERK did not result in an enhancement of
phospo-Thr308-Akt levels in these animals (Figures 3D
and 3E), thus indicating that ERK signaling is not a con-
tributing factor to the deactivation of Akt by DA in the
adult mouse striatum.
Inhibition of PP2A Antagonizes the Negative
Regulation of Akt by Dopamine
Serine/threonine protein phosphatases have been
shown to negatively regulate Akt activity in multiple cel-
lular systems (Andjelkovic et al., 1996; Li et al., 2003;
Ugi et al., 2004). We used intracerebroventricular injec-
tions (i.c.v.) of protein-phosphatase inhibitors in DAT-
KO mice to assess the contribution of phosphatases in
the regulation of Akt by DA. Okadaic acid is a potent
phosphatase inhibitor acting on both PP1 and PP2A
(McCluskey and Sakoff, 2001). Injection of okadaic acid
(100 M, i.c.v.) in the brain of DAT-KO mice resulted in
enhanced phosphorylation of Thr308-Akt as revealed
by Western blot (Figures 4A and 4B). However, changes
in Akt phosphorylation in response to okadaic acid
were not limited to the DA-regulated Thr308 residue.
Phosphorylation of the second regulatory site of Akt
(Ser473) (Alessi et al., 1996) was also enhanced (Fig-
ures 4A and 4B), suggesting that multiple mechanisms
regulating the phosphorylation of Akt in the striatum
Cell
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2A Prevents Inactivation of Akt by Dopamine
(A and B) Western blots (A) and densitomet-
ric analysis (B) of phospho-Thr308 and phos-
pho-Ser473 Akt showing increased Akt
phosphorylation at both residues 30 min
postinjection of the PP1/PP2A inhibitor oka-
daic acid (100 M, i.c.v.) to DAT-KO mice.
(C and D) Western blots (C) followed by den-
sitometric analysis (D) revealed a specific in-
crease of phospho-Thr308 but not phospho-
Ser473 Akt 30 min after injection of the
PP2A-specific inhibitor fostriecin (50 M,
i.c.v.) to DAT-KO mice.
(E and F) Densitometric analysis (F) of West-
ern blots (E) revealed a specific increase of
phospho-Thr308 Akt following administra-
tion of the PP2A-specific inhibitor fostriecin
to amphetamine-treated wt mice. Mice were
first systemically treated with amphetamine
(3 mg/kg) followed 30 min later by i.c.v. injec-
tion of vehicle or fostriecin (50 M, i.c.v.).
Samples were collected 30 min after i.c.v. in-
jection.
(G and H) Western blots (G) and densitomet-
ric analysis (H) showing a decrease in phos-
pho-Thr308 and phospho-Ser473 Akt levels
30 min after i.c.v. injection of the PI3K inhibi-
tor LY294002 (100 M) to DAT-KO mice.
For all analyses, phosphoindependent anti-
bodies directed against the different proteins
were used as loading controls for densitom-
etry. Data are means ± SEM. *, p% 0.05; ***,
p% 0.001. Numbers of animals per group (n)
are indicated.were probably disrupted by this inhibitor. To assess
pwhether more specific inhibition of protein phospha-
tases could oppose the action of DA on Akt phosphory- (
olation, the specific PP2A inhibitor fostriecin (Walsh et
al., 1997) was injected (50 M, i.c.v.) to DAT-KO mice. t
LAs shown in Figures 4C and 4D, inhibition of PP2A re-
sulted in a specific increase in Thr308-Akt phosphoryla- r
Stion in the striatum of DAT-KO mice. To confirm this
observation in normal animals, we explored the conse- t
quences of a specific inhibition of PP2A in wt mice dis- b
playing enhanced DA tones as a result of pharmacolog- u
ical treatment. In this set of experiments, wt mice were
first treated with amphetamine (3 mg/kg, i.p.), followed
S30 min later by fostriecin (50 M, i.c.v.). Western blot
Canalysis was conducted on striatal extracts collected
T30 min after i.c.v. injections. As shown in Figures 4E
βand 4F, administration of the PP2A inhibitor fostriecin
oto amphetamine-treated wt mice resulted in a specific
tenhancement of Thr308-Akt phosphorylation, thus indi-
pcating that β-arrestin 2-mediated deactivation of Akt by
DA involves PP2A. ASince Akt might also be positively regulated through
hosphoinositide 3 kinase (PI3K) mediated signaling
Alessi et al., 1996), we proceeded to evaluate the effect
f PI3K inhibition on Akt phosphorylation in the stria-
um of DAT-KO mice. Injection of the PI3K inhibitor
Y294002 (100 M, i.c.v.) to DAT-KO mice resulted in a
eduction of Akt phosphorylation on both Thr308 and
er473 residues (Figures 4G and 4H), thus indicating
hat PI3K is still active in DAT-KO mice and that its inhi-
ition does not recapitulate the selective action of DA
pon Akt phosphorylation.
triatal Akt, GSK3, and PP2A Subunits Form
omplexes with -Arrestin 2 In Vitro
o further examine the relation between Akt, PP2A, and
-arrestin 2, we verified whether recombinant glutathi-
ne S-transferase β-arrestin 2 (GST-βArr2) could in-
eract with striatal PP2A and Akt. PP2A is a multimeric
rotein complex formed by the assembly of a structural
subunit, a catalytic C subunit, and one of a variety
β-Arrestin 2-Mediated Slow Synaptic Transmission
267of targeting subunits belonging to one of four classes
termed B, B#, B##, and B### (Janssens and Goris, 2001;
Millward et al., 1999). Affinity purification on columns
(GST pulldown) following incubation of GST, GST-βArr1,
or GST-βArr2 recombinant proteins with striatal protein
extracts revealed a copurification of Akt, a targeting B
subunit (55 kDa subunit), and the catalytic C subunit of
PP2A (Millward et al., 1999) from extracts incubated
with GST-βArr2 (Figure 5A). No such copurification of
Akt and PP2A with recombinant proteins was observed
when striatal extracts were incubated with either GST
or GST-βArr1 recombinant proteins (Figure 5A). In con-
trast, both GST-βArr1 and GST-βArr2 were copurified to
levels comparable with their known direct-interaction
partner clathrin (Krupnick et al., 1997), thus suggesting
a preferential interaction of striatal Akt and PP2A sub-
units with β-arrestin 2 (Figure 5A).
Further analysis also revealed the presence of GSK3β
and, to a lesser extent, GSK3α but not the phosphoi-
nositide-dependent protein kinase 1 (PDK1) in GST-
βArr2 eluates (Figure 5B). GSK3α and GSK3β are both
negatively regulated by Akt (Cross et al., 1995) and acti-
vated in response to DA receptor stimulation (Beaulieu
et al., 2004), while PDK1 is a positive regulator of Akt
responsible for the phosphorylation of the Thr308 resi-
due (Alessi et al., 1997). Presence of GSK3α/β but not
PDK1 in GST-βArr2 eluates suggests that the GST-βArr2
recombinant protein specifically interacts with a subset
of the proteins involved in Akt signaling in these assays.
GST-βArr2 and GST-βArr1 were then incubated with
recombinant in vitro-phosphorylated human Akt1 to as-
sess whether Akt can directly interact with β-arrestins
in the absence of other proteins. Western blot analysis
and Coomassie blue-stained SDS-PAGE from GST-pull-
down eluates revealed a copurification of phospho-
Akt1 with recombinant β-arrestin 2 and, to a lesser ex-Figure 5. β-Arrestin 2 Specifically Interacts
with Akt, GSK3, and PP2A In Vitro
(A) GST pulldown showing interaction of stri-
atal Akt, PP2A, B subunit, and C subunit with
β-arrestin 2 but not β-arrestin 1. Clathrin was
used as a positive control of interaction with
β-arrestins. Experiments were repeated at
least two times using separate sets of stria-
tal extracts and recombinant GST fusion
proteins.
(B) GST pulldown showing interaction of stri-
atal Akt and GSK3α and β but not PDK1 with
β-arrestin 2.
(C) GST pulldown showing interaction of re-
combinant phospho-Akt (Thr308 and Ser473)
with β-arrestin 2 and to a lesser extent β-arres-
tin 1. Arrowhead indicates a band correspond-
ing to recombinant Akt on SDS-PAGE stained
with Coomassie blue. E designates lanes
loaded with striatal extract. Std: molecular
weight standard. IB: immunoblot.tent, with β-arrestin 1 (Figure 5C). This indicates that,
while β-arrestin 2 seems to be the preferred interacting
partner of Akt in the striatum, both β-arrestins can in-
teract directly with Akt with different efficiency under in
vitro conditions.
Interaction of Akt, PP2A, and -Arrestin 2
in the Mouse Striatum
We performed immunoprecipitation experiments to con-
firm the results obtained from GST pulldowns. As shown
in Figure 6, immunoprecipitation of Akt from striatum of
wt C57BL/6J mice led to a coimmunoprecipitation of
endogenous B and C subunits of PP2A (Figure 6A). A
separate set of experiments revealed that β-arrestin 2
was preferentially immunoprecipitated over β-arrestin 1
along with Akt (Figure 6B). Moreover, β-arrestin 2 was
selectively coimmunoprecipitated with targeting B sub-
units of PP2A (Figure 6C). Taken together, these results
further substantiate that an interaction of Akt and PP2A
subunits with β-arrestin 2 occurs in the mouse striatum.
Interaction of Akt with PP2A Is Disrupted in Mice
Lacking -Arrestin 2
To further document a role of β-arrestin 2 as a scaffold-
ing intermediate for the interaction of Akt and PP2A,
we performed immunoprecipitation assays in βArr2-KO
mice and wt littermates. In line with results from wt
C57BL/6J mice (Figure 6A), immunoprecipitation of Akt
from the striatum of wt littermates resulted in consis-
tent coimmunoprecipitation of PP2A subunits (Figure
6D). In contrast, immunoprecipitations carried out with
mice lacking β-arrestin 2 revealed a dramatic reduction
in the amount of PP2A subunits interacting with Akt in
the striatum of these mice (Figure 6D). This reduction
was not associated with changes in Akt or PP2A sub-
unit levels in βArr2-KO mice, thus indicating that
Cell
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(A and B) Akt immunoprecipitation assay showing a coimmunoprecipitation of PP2A B subunit and C subunit (A) as well as β-arrestin 2 (B)
along with Akt from protein extracts prepared from the striatum of wt C57BL/6J mice.
(C) Coimmunoprecipitation of β-arrestin 2 and the C subunit of PP2A along with the PP2A B subunit in extracts prepared from the striatum
of wt C57BL/6J mice. Right-hand panel shows that the β-arrestin isoform coimmunoprecipitated with PP2A corresponds to β-arrestin 2.
(D) Coimmunoprecipitation of PP2A along with Akt in striatal extracts prepared from littermate wt but not βArr2-KO mice.
(E) Coimmunoprecipitation of the PP1 catalytic subunit with Akt in striatal extracts prepared from βArr2-KO mice and wt littermates.
(F and G) Western blot (F) and densitometric analysis (G) of levels of PP2A B subunit and PP2A C subunit as compared to Akt in the striatum
of βArr2-KO mice and wt littermates. Average ratios of PP2A subunit to Akt were normalized to 1.00 in wt animals. Data are means ± SEM.
Numbers of animals per group (n) are indicated.
For immunoprecipitations, E designates striatal extract and (−) designates control experiment performed without antibodies. Each track
represents independent immunoprecipitation experiments performed from extracts prepared from the striatum of different mice.β-arrestin 2 is an essential scaffold for the interaction b
7of Akt with PP2A in the mouse striatum (Figures 6F and
6G). Moreover, since PP1 can play some role in Akt reg- c
(ulation (Li et al., 2003), we assessed whether PP1 could
also interact with Akt in a β-arrestin 2-dependent fash- p
eion. As shown in Figure 6E, immunoprecipitation exper-
iments revealed that the catalytic subunit of PP1 could i
be coimmunoprecipitated along with Akt from the
mouse striatum. However, this interaction was not abol- D
ished by the absence of β-arrestin 2 (Figure 6E), thus
directly demonstrating that PP2A, but not PP1, is in- S
volved in the β-arrestin 2-dependent regulation of Akt a
by DA. p
n
tAkt/-Arrestin 2/PP2A Interaction
Is Regulated by Dopamine n
sQuantitative immunoprecipitation experiments were
carried out to establish whether the formation of an t
sAkt/β-arrestin 2/PP2A signaling complex could be de-
pendent on extracellular DA levels. For these experi- v
ements, wt C57BL/6J mice were treated with vehicle or
with a dose of amphetamine (3 mg/kg, i.p.) that is 2
vknown to increase extracellular DA levels and trigger
Akt dephosphorylation (Beaulieu et al., 2004). Western Dlot analysis of immunoprecipitates (Figures 7A and
D) revealed a marked increase in the amount of PP2A
atalytic subunit (Figures 7A and 7B) and β-arrestin 2
Figures 7C and 7D) precipitated with Akt following am-
hetamine administration, thus providing compelling
vidence for the regulation of the Akt/β-arrestin 2/PP2A
nteraction by DA.
iscussion
low synaptic transmission is for the most part medi-
ted by seven transmembrane domain receptors cou-
led to G proteins. In the specific case of dopaminergic
eurotransmission, most behavioral actions of DA are
hought to be associated with the modulation of ade-
ylate cyclase and PKA activity (Greengard, 2001; Mis-
ale et al., 1998). Recent investigations have uncovered
hat stimulation of striatal D2 class receptors also re-
ults in a cAMP-independent dephosphorylation/inacti-
ation of Akt (Beaulieu et al., 2004) associated with the
xpression of DA-dependent behaviors (Beaulieu et al.,
004; Emamian et al., 2004). Here we show, using an in
ivo approach, that DA receptors regulate Akt activity and
A-associated behaviors through a β-arrestin 2-mediated
β-Arrestin 2-Mediated Slow Synaptic Transmission
269Figure 7. Formation of the Akt/β-Arrestin
2/PP2A Signaling Complex Is Regulated by
Dopamine
(A–D) Quantification of the interaction of the
catalytic subunit of PP2A (A and B) or of
β-arrestin 2 (C and D) with Akt as measured
by densitometric analysis (B–D) following
coimmunoprecipitation (A and C) from stria-
tal extracts prepared from vehicle and am-
phetamine (3 mg/kg, 60 min postinjection)
treated C57BL/6J wt mice. Average ratios of
PP2A to Akt or β-arrestin 2 are normalized
to 1.00 in vehicle-treated animals. Data are
means ± SEM. Numbers of animals per
group (n) are indicated. *, p % 0.05.
(E) Working model of the Akt/β-arrestin
2/PP2A signaling complex formed in re-
sponse to activation of DA receptors leading
to Akt inactivation in the mouse striatum.
D2R indicates D2 class receptors (D2S, D2L,
D3, and D4).signaling mechanism that involves a previously uniden-
tified β-arrestin/kinase/phosphatase signaling complex.
These results provide direct physiologically relevant
evidence that β-arrestin 2 participates in slow synaptic
transmission by acting as a scaffold for signaling mole-
cules in response to GPCR activation.
The signaling mechanism described here involves
the formation of a protein complex comprised of at
least Akt, β-arrestin 2, and the multimeric protein phos-
phatase PP2A (Figure 7E). Mice lacking β-arrestin 2 dis-
play reduced responsiveness to dopaminergic drugs
and exhibit lower locomotor activity during the initial
phase of habituation to a novel environment (Figure 1).
Moreover, the DA-dependent locomotor activity of DAT-
KO mice was reduced in mice lacking both DAT and
β-arrestin 2 (Figure 1). These behavioral deficits in βArr2-
KO mice are accompanied by loss of Akt regulation in
response to D2 receptor stimulation (Figure 2). Inhibi-
tion of Akt in response to DA can also be antagonized
by specific inhibition of PP2A in mice exhibiting en-
hanced DA neurotransmission (Figure 4). Furthermore,
β-arrestin 2 plays an essential role in mediating the in-teraction of Akt with a targeting B subunit and the cata-
lytic C subunit of PP2A in response to DA (Figure 5–7).
β-arrestins can act as positive mediators for signal-
ing, leading to activation of protein kinases such as
ERK1/2 and Src through protein scaffolding in cell-cul-
ture systems (Lefkowitz and Shenoy, 2005). However,
the in vivo physiological relevance of β-arrestin-medi-
ated signaling in vivo has remained unclear. Our obser-
vations in mice provide direct evidence for the involve-
ment of β-arrestin-mediated signaling in a physiological
paradigm, namely, dopaminergic slow synaptic trans-
mission. In doing so, these results also introduce the
concept that β-arrestin 2 is not only involved in the pos-
itive regulation of kinase activity but can also mediate
inactivation of certain kinases, here by scaffolding Akt
along with PP2A in response to GPCR stimulation.
Akt has been implicated in the regulation of multiple
biological processes ranging from glycogenesis to em-
bryonic development, inflammation, apoptosis, and cell
proliferation (Scheid and Woodgett, 2001). Our results
show that β-arrestin 2 can play an important function
in Akt regulation by acting as a scaffold between this
Cell
270kinase and its regulatory phosphatase PP2A. Previous a
tobservations in cultured fibroblasts have shown that
β-arrestin 1 but not β-arrestin 2 participates in signaling a
vpathways resulting in Akt activation in response to in-
sulin growth factor 1 (IGF1) or α-thrombin receptor m
rstimulation (Goel et al., 2002; Povsic et al., 2003). How-
ever, no interaction between β-arrestin 1 and Akt has a
fbeen observed in fibroblasts overexpressing these two
proteins (Povsic et al., 2003). Evidence also indicates s
athat β-arrestin 1 would regulate Akt through indirect
signaling pathways involving the activation of Src and m
lPI3K rather than through the direct scaffolding of Akt
(Goel et al., 2002; Povsic et al., 2003). Nevertheless, our A
iobservation in GST-pulldown assays on recombinant
phospho-Akt indicate that, under certain conditions, s
iβ-arrestin 1 can also interact with Akt, albeit with lower
efficacy than with β-arrestin 2. Taken together with pre- 2
rvious observations, the results presented here suggest
that both β-arrestin 1 and β-arrestin 2 may participate t
iin the regulation of Akt through different mechanisms.
This further suggests that, apart from its role in dopa- s
tminergic neurotransmission, β-arrestin-mediated sig-
naling may be relevant to many physiological pro- b
icesses associated with Akt functions.
β-arrestins are known to play a critical role in desen- D
tsitization of GPCRs by binding to receptors following
their agonist-dependent GRK-mediated phosphoryla- e
ction, resulting in termination of receptor-G protein cou-
pling and signaling (Attramadal et al., 1992; Ferguson m
et al., 1996). Thus, β-arrestin or GRK deficiency would
be generally expected to enhance efficacy of GPCR n
tsignaling and physiological response (Gainetdinov et
al., 2003). In fact, mice lacking β-arrestin 2 display en- t
mhanced sensitivity to morphine in tests of pain percep-
tion and reward due to impaired desensitization of h
F-opiod receptors (Bohn et al., 1999; Bohn et al., 2003).
In line with these observations, lack of GRK6, the major w
mGPCR kinase expressed in the striatum, results in
markedly enhanced coupling of D2 class receptors to I
pG proteins and behavioral supersensitivity to dopa-
minergic stimulation (Gainetdinov et al., 2003). How- b
dever, preliminary investigations also revealed that do-
pamine-mediated locomotor responses to drugs are s
treduced in βArr2-KO (Gainetdinov et al., 2004). Here we
substantiate these findings by showing profound re- a
rduction in responses to amphetamine and apomor-
phine and genetically elevated DA neurotransmission in i
2the absence of β-arrestin 2. Such remarkable differ-
ences in consequences of deficiency in molecules as- m
esociated with GPCR desensitization highlight the com-
plex role of these molecules in the regulation of GPCR o
Csignaling. One possible explanation can be that some
receptors are negatively regulated by β-arrestin 2 s
nthrough receptor desensitization/internalization, while
others use this same molecule as a mediator of “posi- b
ctive” signaling. To add to the complexity of this situa-
tion, it is likely that the dual roles of β-arrestins in GPCR o
signaling may be subject to complex regulatory mecha-
nisms in response to different intensity or duration of a
iGPCR stimulation and/or potency of agonists (Nair and
Sealfon, 2003). T
wMost biochemical and behavioral actions of DA have
been studied in relation to activation of cAMP-depen- s
sdent signaling pathways (Greengard, 2001; Missale etl., 1998). Among many PKA substrates, phosphoryla-
ion of the PP1 inhibitor DARPP-32 has been positively
ssociated with the expression of DA-associated beha-
iors (Greengard, 2001). However, mice lacking this
olecule display only partial deficits in their behavioral
esponses to DA drugs (Fienberg et al., 1998; Nally et
l., 2003). Here we show that β-arrestin 2 is essential
or the expression of a major part of the behavioral re-
ponse to the dopaminergic drugs amphetamine and
pomorphine (Figure 1). Furthermore, double-knockout
ice lacking both β-arrestin 2 and DAT have reduced
evels of activity in comparison to DAT-KO littermates.
s shown in this study, lack of β-arrestin 2 did not result
n an inhibition of DARPP-32 phosphorylation in re-
ponse to DA receptor stimulation. However, cAMP-
ndependent regulation of Akt by DA (Beaulieu et al.,
004) was abolished in βArr2-KO mice (Figure 2), thus
evealing a mechanism by which DA modulates Akt ac-
ivity in striatal cells. It is important to note that, like
n mice lacking DARPP-32, DA functions are not fully
uppressed in βArr2-KO mice. These findings suggest
hat an intricate network of signaling pathways in which
oth cAMP-dependent and -independent events play
mportant and perhaps cooperative functions mediate
A actions. Further studies will undoubtedly be needed
o delineate the role of these different pathways in the
xpression of DA-related functions and psychiatric
onditions associated with dysregulation of dopa-
inergic neurotransmission.
Recent evidence has linked dysregulation of Akt sig-
aling pathways with schizophrenia. Reduced Akt pro-
ein levels were shown in the brain of schizophrenic pa-
ients, while Akt1 knockout mice developed behavioral
anifestations that are generally associated with en-
anced dopaminergic functions (Emamian et al., 2004).
urthermore, significant association of Akt1 haplotypes
ith schizophrenia has been reported following trans-
ission-disequilibrium tests (Emamian et al., 2004;
keda et al., 2004). Typical antipsychotics such as halo-
eridol are thought to exert most of their action by
locking D2 class receptors, thus supporting a role for
opaminergic neurotransmission in the etiology of
chizophrenia (Snyder, 1976). Interestingly, administra-
ion of haloperidol or the selective D2 class-receptor
ntagonist raclopride has been shown to prevent the
egulation of Akt by DA or enhance Akt phosphorylation
n animal models (Beaulieu et al., 2004; Emamian et al.,
004). Moreover, two other drugs used in the manage-
ent of psychosis, lithium and clozapine, also act as
nhancers of Akt signaling in vivo (Beaulieu et al., 2004)
r in cell-culture systems (Chalecka-Franaszek and
huang, 1999; Kang et al., 2004). In light of these ob-
ervations, involvement of β-arrestin 2-mediated ki-
ase/phosphatase scaffolding in the regulation of Akt
y DA indicates that β-arrestin 2-mediated signaling
ould contribute to the etiology and/or management
f schizophrenia.
In conclusion, we have shown that a β-arrestin 2-medi-
ted kinase/phosphatase scaffolding of Akt and PP2A
s responsible for the regulation of Akt by DA receptors.
hese observations provide an alternative pathway by
hich D2 class-receptor activation leads to the expres-
ion of DA-associated behaviors. Moreover, these re-
ults provide direct in vivo evidence for the physiologi-
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271cal relevance of β-arrestin-mediated GPCR signaling
while uncovering a previously unappreciated modality,
kinase/phosphatase scaffolding, by which β-arrestins
can participate in signal transduction. Furthermore, in-
vestigations of the function and mechanism of this ki-
nase/phosphatase scaffolding in dopaminergic slow
synaptic transmission should provide new interesting
research avenues to understand and potentially man-
age DA-related human disorders.
Experimental Procedures
Experimental Animals
C57BL/129SvJ DAT-KO and βArr2-KO mice were described pre-
viously (Bohn et al., 1999; Cyr et al., 2003; Giros et al., 1996). βArr2-
KO/DAT-KO mice were derived through a two-step breeding pro-
cedure. First, DAT-KO mice were mated to βArr2-KO mice to obtain
double-heterozygote mice that were then bred to generate double-
KO mice and control littermates having all possible combinations
of the DAT and βArr2 mutant alleles. Three-month-old male wt
C57BL/6J mice were obtained from Jackson Laboratory. For all ex-
periments involving knockout animals, respective wt littermates
were used as controls, and all mice used were of between 3 and 4
months of age. Before experiments, animals were housed four or
five to a cage at 23°C on a 12 hr light/12 hr dark cycle with ad
libitum access to food and water. Animal care was approved by the
Institutional Animal Care and Use Committee and followed National
Institutes of Health guidelines.
Antibodies
The anti-phospho-Akt Thr308, anti-phospho-Akt Ser473, anti-total-
Akt, anti-PDK1, anti-phospho-DARPP-32 Thr34, and anti-ERK
polyclonal antibodies as well as the anti-phospho-ERK1/2 (Thr202/
Tyr204) monoclonal antibody were purchased from Cell Signaling
Technology (Beverly, Massachusetts). Anti-DARPP-32 and anti-
clathrin monoclonal antibodies were obtained from BD Transduc-
tion Laboratories (Lexington, Kentucky). The anti-GSK3α/β clone
0011-A and the anti-PP1 C subunit antibodies were from Santa
Cruz Biotechnology (Santa Cruz, California). The anti-actin clone
c4 was from Chemicon (Temecula, California). The anti-PP2A, B,
and C subunit monoclonal antibodies were from Upstate (Char-
lottesville, Virginia). The polyclonal anti-β-arrestin antibodies have
been described previously (Attramadal et al., 1992).
Drug Administration
Amphetamine and apomorphine (Sigma-Aldrich, St. Louis) were
dissolved in saline or distilled water containing 0.1% ascorbate,
respectively, and injected i.p. (amphetamine) or s.c. (apomorphine).
SL327 (Tocris Cookson Inc., Ellisville, Missouri) was injected i.p.
after suspension in a minimal amount of Tween and made up to
volume with distilled water. Okadaic acid (Calbiochem, Cambridge,
Massachusetts) and fostriecin (Sigma-Aldrich) were prepared in
50% DMSO in artificial cerebrospinal fluid and injected i.c.v. in a
volume of 4 l at a rate of 1 l/min as described (Beaulieu et al.,
2004). LY294002 (Sigma-Aldrich) was dissolved in a minimal volume
of ethanol prior to being diluted in artificial cerebrospinal fluid and
injected i.c.v.. Corresponding vehicle solutions were injected to re-
spective control animals.
Western Blot Analysis
Western blot analyses were performed as described in Beaulieu et
al. (2004).
Immunoprecipitations
Immunoprecipitations were carried out as described in Beaulieu et
al. (2004) using either 30 l of immobilized anti-Akt antibody (Cell
Signaling Technology) or a monoclonal anti-PP2A B subunit anti-
body followed by a 2 hr incubation with protein G Sepharose (Am-
ersham Bioscience).GST Affinity Purification
GST-tagged constructs in pGEX-4T-1 expression vector (Amer-
sham Bioscience) were transformed in Escherichia coli competent
cells. Overnight cultures were grown from a single bacterial clone
in LB medium supplemented with carbenicillin (50 g/ml), diluted
to an A600 of 0.2 in the same medium, and then induced with 0.1
mM isopropyl-1-thio-β-D-galactopyranoside for 5 hr at 37°C. Cells
were then pelleted; washed once with phosphate-buffered saline
(PBS); resuspended in PBS containing protease inhibitors, 1 mM
phenylmethylsulfonyl fluoride, 10 mM dithiothreitol, 100 mM MgCl2,
1 mg/ml lysozyme, and 1.7 U/ml DNase; and incubated for 30 min
on ice. Cells were lysed by two freeze-thaw cycles followed by
incubation for 30 min on ice and centrifuged at 16,000 rpm in a
Sorvall SS-34 rotor for 45 min.
For experiments involving striatal protein extracts, ten mouse
striata were homogenized in TE buffer (10 mM Tris-HCl [pH 7.4], 2
mM EDTA, 1.0% Triton X-100) containing protease inhibitors, incu-
bated for 30 min on ice, and spun at 16,000 rpm in a Sorvall SS-34
rotor for 45 min. Recombinant phosphorylated Akt1 was purchased
from Upstate.
Binding assays were performed using GSTrap FF affinity columns
(Amersham Bioscience). Bacterial lysates containing either GST rat
GST-β-arrestin 1 or rat GST-β-arrestin 2 constructs as well as stria-
tal extracts or recombinant Akt1 were filtered through a 22 m filter
before they were sequentially applied to the columns using a peri-
staltic pump. The GST fusion proteins were eluted with 5 column
volumes of elution buffer (50 mM Tris-HCl, 10 mM reduced glutathi-
one [pH 8]). Samples were collected and protein concentration was
determined using a DC protein-assay kit. Equal amounts of pro-
teins were subjected to SDS-PAGE under denaturating conditions,
transferred to nitrocellulose, analyzed by Ponceau staining, and
subjected to Western blot analysis. Alternatively, SDS-PAGE gels
were stained using Biosafe Coomassie (Bio-Rad Laboratories,
Inc.).
Measurement of Locomotor Activity
Various parameters of locomotor activity in mice were evaluated as
previously described (Beaulieu et al., 2004; Gainetdinov et al., 1999;
Wang et al., 1997).
Statistical Analysis
Data were analyzed by two-tailed t test or one-way ANOVA. Values
in graphs were expressed as mean ± SEM.
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